V
Vincent C. O. Njar
Researcher at University of Maryland, Baltimore
Publications - 154
Citations - 10648
Vincent C. O. Njar is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Prostate cancer & Androgen receptor. The author has an hindex of 42, co-authored 146 publications receiving 9790 citations. Previous affiliations of Vincent C. O. Njar include Saarland University & University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Papers
More filters
Journal ArticleDOI
Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.
Lalji K. Gediya,Aakanksha Khandelwal,Jyoti Patel,Aashvini Belosay,Gauri Sabnis,Jhalak Mehta,Puranik Purushottamachar,Vincent C. O. Njar +7 more
TL;DR: Novel mutual prodrugs of ATRA and HDIs connected via glycine acyloxyalkyl carbamate linker or through a benzyl ester linker were rationally designed and synthesized and exhibited differential antiproliferative potencies in both MDA-MB-231 and PC-3 cell lines.
Journal ArticleDOI
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Jyoti Patel,Jhalak Mehta,Aashvini Belosay,Gauri Sabnis,Aakanksha Khandelwal,Angela Brodie,Angela Brodie,D R Soprano,Vincent C. O. Njar,Vincent C. O. Njar +9 more
TL;DR: The results suggest that the RAMBAs, especially VN/14-1 may be useful novel therapy for breast cancer, being as effective as the clinically used aromatase inhibitors, anastrozoles and letrozole.
Journal ArticleDOI
Targeting Cytochrome P450 Enzymes: A New Approach in Anticancer Drug Development
Journal ArticleDOI
Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments.
TL;DR: The current state of anti-androgen therapy, mainly for CRPC, is detailed, with major emphasis on the most potent and promising compounds under development.
Journal ArticleDOI
Synthesis of 6-hydroximino-3-oxo steroids, a new class of aromatase inhibitor
TL;DR: (E)-3β,17β-Dihydroxyandrost-4-en-6-one oxime has been converted into (E)-6- hydroximinotestosterone and (E)6-hydroximinoandrosta-1,4-diene-3,17-dione by biotransformation using Arthrobacter simplex ATCC 6946.